Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.67 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.67 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.67 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16806828 | 0.92 | GUCY1B2 (0.66) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16806827 | 0.91 | GUCY1B2 (0.66) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16806965 | 0.89 | GUCY1B2 (0.68) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL16806617 | 0.88 | GUCY1B2 (0.53) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16806613 | 0.87 | GUCY1B2 (0.68) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16806611 | 0.86 | GUCY1B2 (0.56) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16806616 | 0.84 | GUCY1B2 (0.55) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16906928 | 0.84 | GUCY1B2 (0.65) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16806983 | 0.84 | GUCY1B2 (0.53) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL17621688 | 0.83 | GUCY1B2 (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214364-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3092231-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | CYCLERION THERAPEUTICS, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | CYCLERION THERAPEUTICS, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160311826-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311826-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| WO-2015106268-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015089182-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | SMN1; SMN2, PRKG1, GUCY1A2 | GUCY1B2 8/4885GUCY1A2 3/4885GUCY1A1 6/4885 |
| US-20160311826-A1 | SGC STIMULATORS | GUCY1A1, GUCY1B1, GUCY1A2 | GUCY1B2 4/4885GUCY1A2 3/4885GUCY1A1 1/4885 |
| US-20210214364-A1 | sGC STIMULATORS | GUCY1B1, GUCY1A1, GUCY1B2 | GUCY1B2 3/4885GUCY1A2 4/4885GUCY1A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.